China – One of the candidates for a Covid-19 vaccination has completed its second clinical trial, reported the China National Biotec Group, which has been leading the operation.
In a statement released by the company, it revealed that all 1,120 people who took part in the trials showed no serious side effects after receiving the vaccine, which is the first inactivated vaccine for the coronavirus approved for clinical trial globally.
In addition to this, the study also observed a high concentration of antibodies produced in the bodies of all those who received the vaccine, which supports the effectiveness of the vaccine.
The clinical trials began on April 12th in Wuzhi County, Henan.
Participants, all aged between 18 and 59 were divided into groups and received different dozes of the vaccine over the course of 14, 21 and 28 days, with each participant receiving a total of two shots.
The company also highlighted that the clinical result has been the best among all other similar COVID-19 vaccines being researched in China.
